TransMedics Group (NASDAQ:TMDX) Shares Gap Up – Time to Buy?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) gapped up before the market opened on Tuesday . The stock had previously closed at $64.05, but opened at $67.42. TransMedics Group shares last traded at $65.03, with a volume of 673,822 shares trading hands.

Analyst Ratings Changes

A number of analysts have commented on the stock. Oppenheimer restated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Finally, Canaccord Genuity Group reduced their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Down 0.0 %

The stock’s fifty day moving average is $73.56 and its two-hundred day moving average is $120.20. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $2.15 billion, a PE ratio of 68.11 and a beta of 2.12.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period last year, the company earned ($0.12) earnings per share. As a group, analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Park Avenue Securities LLC increased its position in shares of TransMedics Group by 3.8% in the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock worth $548,000 after purchasing an additional 322 shares during the last quarter. Claro Advisors LLC bought a new position in shares of TransMedics Group in the fourth quarter worth approximately $297,000. Harbour Capital Advisors LLC increased its position in shares of TransMedics Group by 33.3% in the fourth quarter. Harbour Capital Advisors LLC now owns 6,452 shares of the company’s stock worth $446,000 after purchasing an additional 1,611 shares during the last quarter. Talbot Financial LLC bought a new position in shares of TransMedics Group in the fourth quarter worth approximately $300,000. Finally, Fiduciary Alliance LLC bought a new position in shares of TransMedics Group in the fourth quarter worth approximately $247,000. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.